A cystic fibrosis patient with acute respiratory decline achieved clinical recovery through intravenous bacteriophage therapy combined with antibiotics, targeting drug-resistant bacterial infection. Multi-omics analysis revealed how engineered phages disrupted bacterial biofilms while antibiotics eliminated remaining pathogens. This represents a pivotal demonstration of phage therapy's clinical viability for treating antibiotic-resistant infections in vulnerable populations. The approach addresses a critical gap in treating chronic respiratory infections that standard antibiotics cannot clear. While promising, this single case study requires replication across larger patient cohorts to establish safety profiles and optimal dosing protocols. The multi-omics methodology provides a blueprint for personalizing phage selection based on individual bacterial resistance patterns. For adults with chronic inflammatory conditions or compromised immune systems, this therapeutic strategy could offer hope when conventional treatments fail. However, regulatory pathways for personalized phage therapy remain undefined, and manufacturing challenges could limit immediate accessibility. The success suggests we're entering an era where precision microbiology—matching specific phages to bacterial strains—becomes standard care for severe resistant infections.